MiRNA-96 accelerates the malignant progression of ovarian cancer via targeting FOXO3a.

CONCLUSIONS: The knockdown of miRNA-96 attenuated the proliferative and migratory abilities in OC cells by targeting FOXO3a. We believed that miRNA-96 accelerates the malignant progression of OC, which could be utilized as a therapeutic target in clinical application. PMID: 31957819 [PubMed - in process]

https://www.ncbi.nlm.nih.gov/pubmed/31957819?dopt=Abstract

Source: European Review for Medical and Pharmacological Sciences - January 21, 2020 Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research